High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit / triple-hit) · line 2 · Axicabtagene ciloleucel (axi-cel CAR-T) for relapsed/refractory HGBL-DH
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CAR-T-AXICEL-HGBL |
| ID | IND-HGBL-DH-2L-CART-AXICEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-HGBL-DH |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 SRC-ZUMA-1-NEELAPU-2017 SRC-ZUMA-7-LOCKE-2022 |
Notes
Aggressive-track 2L for HGBL-DH. UA access barrier: CAR-T not commercially available — international referral pathway only. Alternative 2L (standard track) for chemorefractory or no CAR-T access: salvage R-ICE/R-DHAP + autoSCT — separate Indication when scope opens.
Used By
Algorithms
ALGO-HGBL-DH-2L- ALGO-HGBL-DH-2L